Alzamend pursuing additional indications of bipolar disorder, major depressive disorder and post-traumatic stress disorder for AL001
ATLANTA, October 05, 2022--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease ("Alzheimer’s"), bipolar disorder, major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it has dosed its first healthy adult subject in its Phase IIA multiple ascending dose ("MAD") study of AL001 in subjects with dementia related to Alzheimer’s. This blinded, placebo-controlled trial (AL001-02) was initiated in May 2022 and is designed to evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose.
Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD. Based upon a recommendation by the U.S. Food and Drug Administration ("FDA") after its review and commentary on Alzamend’s pre-investigational new drug ("IND") briefing package for development of AL001 for bipolar disorder, MDD and PTSD, the ongoing clinical trial in Alzheimer’s patients has been expanded. As the safety and tolerability of AL001 would need to be tested in healthy and elderly adults before Alzamend could initiate later-stage testing of AL001 for bipolar disorder, MDD and PTSD, the addition of healthy and elderly adults to the on-going AL001-02 clinical trial would expedite the timing of further clinical trials. Alzamend will test AL001 in four healthy adult and elderly adult cohorts of eight subjects under MAD conditions.
AL001, a novel lithium-salicylate-L-proline engineered ionic cocrystal lithium delivery system, is under development as an oral treatment for patients with Alzheimer’s disease, and more recently for other neurodegenerative and neuropsychiatric disorders. AL001 has the potential to deliver benefits of marketed lithium carbonate while mitigating or avoiding current toxicities associated with lithium. In a Phase I relative bioavailability comparison of AL001 to lithium carbonate completed in March 2022, AL001 was shown to be bioequivalent at 50% less the dosage of lithium carbonate and the shapes of the lithium plasma concentration versus time curves were similar. Additionally, AL001 salicylate plasma concentrations were observed to be well tolerated and consistently within safe limits and the safety profiles of both AL001 and the marketed lithium carbonate capsule were benign.
"Adding healthy adult and elderly subjects to the Phase IIA MAD clinical trial is in response to recent FDA guidance regarding our forthcoming INDs for AL001 as a treatment of bipolar disorder, MDD and PTSD," said Stephan Jackman, Chief Executive Officer of Alzamend. "We are one step closer to providing patients, caregivers and clinicians with a major improvement over current lithium-based treatments that can help over 40 million Americans suffering from Alzheimer’s, bipolar disorder, MDD and PTSD. We look forward to completing the AL001-02 study and further advancing clinical development of this promising potential therapeutic."
Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, bipolar disorder, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate, and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005399/en/
Email: Info@Alzamend.com or call: 1-844-722-6333
Investors are facing a storm of headwinds right now – a genuine bear market, stubbornly high inflation, rising interest rates, and increased fears of a recession in the near-term. However, Mary Callahan Erdoes, CEO of JPMorgan's Asset & Wealth Management division, advises investors to stay invested. "It's actually the easiest time in the world to find alpha — there is alpha everywhere... It's everywhere, because we are in such a state of change... While all the world is focused on all the black
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
One of the great things about investing in stocks is that you don't need millions of dollars in the bank to get started. Let's look at an incredible healthcare stock whose shares are changing hands for just about $44 (as of this writing): Pfizer (NYSE: PFE). Pfizer is a major pharmaceutical company with a rich lineup of medicines and vaccines.
Health officials say the strain is worrisome because it may evade prior protections and not respond to current vaccines.
Tests from Grail and others aim to help clinicians diagnose more cancers earlier, though data are limited.
The cuts are intended to reduce costs, streamline operations and increase profitability for BioMarin, frequently tapped as a likely takeover target.
Bank of America analysts on Friday told investors that Eli Lilly & Co. Inc.’s (LLY) diabetes treatment and possible weight-management drug could be a $100 billion medication. The drug, tirzepatide, received Food and Drug Administration approval as a treatment for Type 2 diabetes earlier this year. It has also shown in clinical trials that it can help people lose up to 20% of their body weight.
COVID fatigue is very real. Here's how long covid fatigue lasts, plus treatment tips to help you get your energy back.
Medicare’s annual open enrollment period begins on Oct. 15 and ends on Dec. 7. More than seven in 10 Medicare beneficiaries did not even compare plans during this period in 2018, according to the Kaiser Family Foundation, a nonprofit group focused on health policy. Many times, it’s because making the change — or just reviewing the options — can be overwhelming, said Dave Francis, chief executive officer and co-founder of Healthpilot, a company whose services include automated and personalized Medicare plan recommendations.
Wonder Pill quietly contained a drug used to treat erectile dysfunction, which could be deadly for some unknowing consumers, the FDA said.
Contrary to popular belief, the simple approach to many things in life is often the most effective. An investing quote from Motley Fool contributor Brian Feroldi that I believe is highly underrated goes as follows: "Good investing is 99% patience and 1% action." The pharmaceutical giant Amgen (NASDAQ: AMGN) and medical devices maker Stryker (NYSE: SYK) are two healthcare stocks that appear poised to create wealth for shareholders who are patient and measured enough to let them.
Senate Republicans on Friday introduced a bill that would roll back the drug pricing reforms included in the sweeping Inflation Reduction Act, including the measures allowing Medicare to negotiate drug prices and capping annual drug expenses for many seniors. Republican Sens. James Lankford (Okla.), Mike Lee (Utah), Cynthia Lummis (Wyo.) and Marco Rubio (Fla.) introduced…
Eli Lilly said Thursday it plans to begin the process of asking the FDA to approve its obesity treatment. LLY stock rose on the news.
Cannabis stocks dropped Friday after President Joe Biden on Thursday announced pardons for thousands of people convicted of marijuana possession under federal law. The president called on governors to take similar action for state offenses. Biden also said his administration will review whether cannabis should remain in its current federal category along with heroin and LSD — a move widely...
Oramed Pharmaceuticals Inc's (NASDAQ: ORMP) subsidiary, Oravax Medical Inc, reported preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in most patients dosed. No safety issues were observed, including mild symptoms. An open-label, Phase 1 trial will evaluate the safe
All passengers, including U.S. citizens and residents, who have been in Uganda in the last 21 days will be flown to airports in New York, Newark, Atlanta, Chicago or Washington.
Medicare's annual open enrollment period is just around the corner. Between Oct. 15 and Dec. 7, seniors can make changes to their plans for 2023. But before you dive into the new options, it's helpful to know about some big changes the government has made to the program for next year.
More seniors than any other age group died from COVID-19 this past summer amid a disease surge fueled by new subvariants, according to a new analysis published Thursday from the Kaiser Family Foundation. The foundation analyzed COVID-19 data from the Centers for Disease Control and Prevention (CDC) and found that death rates rose much faster…
One of the largest hospital chains in the U.S. was hit with a suspected ransomware cyberattack this week, leading to delayed surgeries, hold ups in patient
The star's husband spent more than a year in hospital.